The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models.
Holt, Sarah V LogiƩ, A Odedra, R Heier, A Heaton, S Alferez, D Davies, B Wilkinson, R Smith, P
Holt, Sarah V
LogiƩ, A
Odedra, R
Heier, A
Heaton, S
Alferez, D
Davies, B
Wilkinson, R
Smith, P
Citations
Altmetric:
Abstract
The Ras/RAF/MEK/ERK pathway is frequently deregulated in cancer and a number of inhibitors that target this pathway are currently in clinical development. It is likely that clinical testing of these agents will be in combination with standard therapies to harness the apoptotic potential of both the agents. To support this strategy, it has been widely observed that a number of chemotherapeutics stimulate the activation of several intracellular signalling cascades including Ras/RAF/MEK/ERK. The MEK1/2 inhibitor selumetinib has been shown to have anti-tumour activity and induce apoptotic cell death as a monotherapy.
Description
Date
2012-02-28
Publisher
Collections
Keywords
Type
Article
Citation
The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models. 2012, 106 (5):858-66 Br J Cancer